Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Tunisia.
Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Tunisia.
Arch Pediatr. 2022 May;29(4):287-291. doi: 10.1016/j.arcped.2021.11.019. Epub 2022 Mar 16.
This study aimed to explore the treatment modalities of relapsed osteosarcoma, treatment results, and prognostic factors.
We conducted a retrospective study of patients treated for relapsed osteosarcoma between 2005 and 2019. Patient survival was compared according to age, performance status, time to relapse, and surgical treatment at the relapse. Values of p<0.05 were considered to indicate statistical significance.
We included 49 patients who were treated for osteosarcoma. During the 13-year study period, 16 patients had relapsed osteosarcoma (32.7%). Prognostic factors of relapse were age over 18 years (p = 0.03), axial tumors (p = 0.01), and positive surgical margins (p = 0.018). Nine patients had palliative chemotherapy at the time of relapse. After a median follow-up of 8 months (range: 4-65 months), the overall survival at 1 year, 2 years, and 5 years after diagnosis of the relapse was 46.7%, 31.1%, and 20.7%, respectively. Relapsed osteosarcoma patients who had good performance status, late relapse (after 12 months), as well as surgery of the relapsed disease had better overall survival (OS).
Surgical treatment of relapsed osteosarcoma should be performed whenever possible since it improves significantly the survival of patients. Good performance status and late relapse were also associated with better survival.
本研究旨在探讨骨肉瘤复发患者的治疗方式、治疗效果和预后因素。
我们对 2005 年至 2019 年期间接受骨肉瘤复发治疗的患者进行了回顾性研究。根据年龄、身体状况、复发时间和复发时的手术治疗情况对患者的生存情况进行了比较。p 值<0.05 被认为具有统计学意义。
我们纳入了 49 例接受骨肉瘤治疗的患者。在 13 年的研究期间,有 16 例患者出现骨肉瘤复发(32.7%)。复发的预后因素包括年龄大于 18 岁(p=0.03)、轴性肿瘤(p=0.01)和阳性手术切缘(p=0.018)。9 例患者在复发时接受了姑息性化疗。在中位随访 8 个月(范围:4-65 个月)后,复发后 1 年、2 年和 5 年的总生存率分别为 46.7%、31.1%和 20.7%。身体状况良好、复发时间较晚(12 个月后)以及对复发疾病进行手术的复发骨肉瘤患者总生存率更高。
只要有可能,就应进行复发骨肉瘤的手术治疗,因为这可以显著提高患者的生存率。身体状况良好和复发时间较晚与更好的生存相关。